Mononucleosis Diagnostic Market Research Report Information By Test Type (Epstein Barr Virus (EBV) Antibody Test, Monospot Test, and Complete Blood Count Test), By End-User (Hospitals, Laboratories, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest of The World) –Market Forecast Till 2032.

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE

6.1. Overview

6.2. Epstein Barr Virus (EBV) Antibody Test

6.3. Monospot Test

6.4. Complete Blood Count Test

7. GLOBAL MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER

7.1. Overview

7.2. Hospitals

7.3. Laboratories

7.4. Others

8. GLOBAL MONONUCLEOSIS DIAGNOSTIC MARKET, BY REGION

8.1. Overview

8.1. North America

8.1.1. US

8.1.2. Canada

8.2. Europe

8.2.1. Germany

8.2.2. France

8.2.3. UK

8.2.4. Italy

8.2.5. Spain

8.2.6. Rest of Europe

8.3. Asia-Pacific

8.3.1. China

8.3.2. India

8.3.3. Japan

8.3.4. South Korea

8.3.5. Australia

8.3.6. Rest of Asia-Pacific

8.4. Rest of the World

8.4.1. Middle East

8.4.2. Africa

8.4.3. Latin America

9. COMPETITIVE LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global Mononucleosis Diagnostic Market,

9.5. Competitive Benchmarking

9.6. Leading Players in Terms of Number of Developments in the Global Mononucleosis Diagnostic Market,

9.7. Key developments and Growth Strategies

9.7.1. New Product Launch/Service Deployment

9.7.2. Merger & Acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix

9.8.1. Sales & Operating Income, 2023

9.8.2. Major Players R&D Expenditure. 2023

10. COMPANY PROFILES

10.1. Abbott (U.S.)

10.1.1. Company Overview

10.1.2. Financial Overview

10.1.3. Products Offered

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. DAIICHI SANKYO COMPANY, LIMITED (JAPAN)

10.2.1. Company Overview

10.2.2. Financial Overview

10.2.3. Products Offered

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. Weizmann Institute of Science (Israel)

10.3.1. Company Overview

10.3.2. Financial Overview

10.3.3. Products Offered

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. Biotest AG (Germany)

10.4.1. Company Overview

10.4.2. Financial Overview

10.4.3. Products Offered

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Bio-Rad Laboratories, Inc. (U.S.)

10.5.1. Company Overview

10.5.2. Financial Overview

10.5.3. Products Offered

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. GENZYME (U.S.)

10.6.1. Company Overview

10.6.2. Financial Overview

10.6.3. Products Offered

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. F. Hoffmann-La Roche Ltd (Switzerland)

10.7.1. Company Overview

10.7.2. Financial Overview

10.7.3. Products Offered

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. JOHNSON & JOHNSON SERVICES, INC. (U.S.)

10.8.1. Company Overview

10.8.2. Financial Overview

10.8.3. Products Offered

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. BD (U.S.)

10.9.1. Company Overview

10.9.2. Financial Overview

10.9.3. Products Offered

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. DIASORIN MOLECULAR LLC (U.S.)

10.10.1. Company Overview

10.10.2. Financial Overview

10.10.3. Products Offered

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

11. APPENDIX

11.1. References

11.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL MONONUCLEOSIS DIAGNOSTIC MARKET, SYNOPSIS, 2019-2032

TABLE 2 GLOBAL MONONUCLEOSIS DIAGNOSTIC MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)

TABLE 3 GLOBAL MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 4 GLOBAL MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 5 NORTH AMERICA: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 6 NORTH AMERICA: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 7 US: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 8 US: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 9 CANADA: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 10 CANADA: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 11 EUROPE: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 12 EUROPE: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 13 GERMANY: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 14 GERMANY: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 15 FRANCE: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 16 FRANCE: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 17 ITALY: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 18 ITALY: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 19 SPAIN: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 20 SPAIN: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 21 UK: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 22 UK: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 23 REST OF EUROPE: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 24 REST OF EUROPE: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 25 ASIA-PACIFIC: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 26 ASIA-PACIFIC: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 27 JAPAN: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 28 JAPAN: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 29 CHINA: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 30 CHINA: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 31 INDIA: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 32 INDIA: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 33 AUSTRALIA: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 34 AUSTRALIA: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 35 SOUTH KOREA: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 36 SOUTH KOREA: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 37 REST OF ASIA-PACIFIC: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 38 REST OF ASIA-PACIFIC: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 39 REST OF THE WORLD: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 40 REST OF THE WORLD: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 41 MIDDLE EAST: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 42 MIDDLE EAST: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 43 AFRICA: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 44 AFRICA: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

TABLE 45 LATIN AMERICA: MONONUCLEOSIS DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2032 (USD BILLION)

TABLE 46 LATIN AMERICA: MONONUCLEOSIS DIAGNOSTIC MARKET, BY END-USER, 2019-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL MONONUCLEOSIS DIAGNOSTIC MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL MONONUCLEOSIS DIAGNOSTIC MARKET

FIGURE 4 GLOBAL MONONUCLEOSIS DIAGNOSTIC MARKET, SHARE (%), BY TEST TYPE, 2023

FIGURE 5 GLOBAL MONONUCLEOSIS DIAGNOSTIC MARKET, SHARE (%), BY END-USER, 2023

FIGURE 6 GLOBAL MONONUCLEOSIS DIAGNOSTIC MARKET, SHARE (%), BY REGION, 2023

FIGURE 7 NORTH AMERICA: MONONUCLEOSIS DIAGNOSTIC MARKET, SHARE (%), BY REGION, 2023

FIGURE 8 EUROPE: MONONUCLEOSIS DIAGNOSTIC MARKET, SHARE (%), BY REGION, 2023

FIGURE 9 ASIA-PACIFIC: MONONUCLEOSIS DIAGNOSTIC MARKET, SHARE (%), BY REGION, 2023

FIGURE 10 REST OF THE WORLD: MONONUCLEOSIS DIAGNOSTIC MARKET, SHARE (%), BY REGION, 2023

FIGURE 11 GLOBAL MONONUCLEOSIS DIAGNOSTIC MARKET: COMPANY SHARE ANALYSIS, 2023 (%)

FIGURE 12 ABBOTT (U.S.): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 13 ABBOTT (U.S.): SWOT ANALYSIS

FIGURE 14 DAIICHI SANKYO COMPANY, LIMITED (JAPAN): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 15 DAIICHI SANKYO COMPANY, LIMITED (JAPAN): SWOT ANALYSIS

FIGURE 16 WEIZMANN INSTITUTE OF SCIENCE (ISRAEL): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 WEIZMANN INSTITUTE OF SCIENCE (ISRAEL): SWOT ANALYSIS

FIGURE 18 BIOTEST AG (GERMANY): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 BIOTEST AG (GERMANY): SWOT ANALYSIS

FIGURE 20 BIO-RAD LABORATORIES, INC. (U.S.): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 BIO-RAD LABORATORIES, INC. (U.S.): SWOT ANALYSIS

FIGURE 22 GENZYME (U.S.): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 GENZYME (U.S.): SWOT ANALYSIS

FIGURE 24 F. HOFFMANN-LA ROCHE LTD (SWITZERLAND). : FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 F. HOFFMANN-LA ROCHE LTD (SWITZERLAND). : SWOT ANALYSIS

FIGURE 26 JOHNSON & JOHNSON SERVICES, INC. (U.S.): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 JOHNSON & JOHNSON SERVICES, INC. (U.S.): SWOT ANALYSIS

FIGURE 28 BD (U.S.): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 BD (U.S.): SWOT ANALYSIS

FIGURE 30 DIASORIN MOLECULAR LLC (U.S.): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 DIASORIN MOLECULAR LLC (U.S.): SWOT ANALYSIS